Medipost/Samsung Hospital joint to develop a new composite for lung disease.

Medipost, a biotech company, has developed a therapeutic composite material for the treatment of lung diseases by the use of adult stem cells in association with the Dept. of Pediatrics, Seoul Samsung Hospital.

The composite materials are formulated with adult stem cells prepared from the umbilical code blood by pure isolation and cultivation and injected into the lung through a bronchi, the...